Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
art35 what you are missing here is that WDDD's CEO went to Activivison years ago to form a partnership. ATVI then turned around a screwed WDDD by STEALING their patents. That right there is going to be CONCRETE evidence and your little appeal plan would only HURT them as it will only UP the ante of the payout they'll have to pay.
DDobserver, my my a lot of babbling for someone that thinks he's a shrink and Cramer all wrapped up in one.
Like I stated, I think your FOS and no there is no anger in that just truth. Why do you say? Well for one you never supplied this board with any PROOF or what you say. So back to what I stated.
Fear Mongering? Now that's a good one chump.
DDobserver, I'll bet you're FOS. What you say to that chump?
PatentPlays, how would one play this stock? Hold long and see if Thom can grow the company into the WiLan type company you spoke of in an earlier post. Or sell right prior to the Markman hearing then reenter if they win it and it goes to trial?
Also I would say Activision is going to appeal any verdict down the line or do you think Susman Godfrey has such a solid case they will settle prior to a jury trial?
PatentPlays, so you do feel that the latest patent cases being thrown out by the courts will NOT affect Worlds case with Activision?
http://www.bloomberg.com/news/2014-09-16/virnetx-to-vringo-s-lost-millions-show-patent-peril.html?cmpid=yhoo
ELTP's technology is the same as what several others are working on and one pharma has already had it brought to market. Using Naltrexone beads. From all my research that toward the bottom of the list on formulas. So there really isn't even a comparison to the two. Especially since one Naltrexone product is already on the market. I think that the FDA wants to see NEW innovated products on the market that are BETTER than the last.
http://www.contractpharma.com/issues/20131101/view_features/abuse-deterrent-formulations/
Been a long road that is for sure
Not to offend you but this "horse" crap has gotten very old.
tonypro99, let's see how can I say this nicely? Hummm can't find one. I think you're FOS
Yea but at this rate you'll be 95 when the 3rd ANDA hits the market.
Found out they have something like 241M in the float so that's not too bad.
One reason this stock sits under a $1.00 is that Gene Therapy has yet to prove it works. But CRXM is getting very close.
http://www.bostonglobe.com/business/2013/06/01/after-disappointments-time-now-for-gene-therapy/wMIbxUe3Fc6szlLHccmYMJ/story.html
Alan Smith can still recall his excitement, in the early 1990s, over early experiments in lab rats that demonstrated gene therapy’s potential power to attack diseases such as cystic fibrosis.
Smith, a former chief scientific officer at Genzyme, the Cambridge biotech company, remembers feeling like the experiments were “steppingstones” to developing a whole new wave of medicines for untreatable diseases. Often, they were touted in Genzyme’s annual reports, and the research was funded with tens of millions of dollars from stock market investors.
But more than two decades later, there is still no gene therapy that has won approval from the US Food and Drug Administration, and Genzyme gave up on it as a potential approach to treating cystic fibrosis. What seemed in the 1990s to be a new world just over the horizon kept receding. There were years of “slow, quiet progress,” in Smith’s words, but also setbacks, including deaths and complications for patients who enrolled in early trials.
This is the article that was in reference and it was original June 29th.
http://www.biospectrumasia.com/biospectrum/news/216642/us-bio-2014-a-gene-therapy-treat-heart-disease-promise
So please know what you are talking about before you make a fool of yourself again.
I don't know where it will be in 6 months.
Partnering with Taxus was the best thing to happen to this company. I'd like to see the details of that partnership. Taxus will be selling their Taxol(paclitaxel)cancer drug ingredient here in the USA. There is always a shortage of paclitaxel.
http://www.ashp.org/menu/DrugShortages/CurrentShortages/bulletin.aspx?id=790
I've worked in the healthcare since 1992 and worked a lot in the Cardiac Thoracic ICU. If Gernerx gets approved they'll be a huge demand for it worldwide. I'm amazed a mid Phase III stock with a potential blockbuster drug is sitting under a $1.00
Yes I know the company has had it's share of set backs but what microcap biotech hasn't. I was just lucky to find this stock AFTER it did the reverse split and then falls back under a $1.00
I can see why many investors are sour on this company. But that's all part of investing in these microcap biotechs though. It's a rollercoaster ride to say the least. But if one finally hits as this one seems to be on the verge of it's a glorious day.
I emailed Jason Napodano about this company and he said he'd never heard of them but would look into them.
http://seekingalpha.com/author/jason-napodano-cfa
With the low float this thing has now the stock will rise extremely fast if Generx gets approval and they have a partner lined up to sell it. Someone like say Merck, Abbotts ,etc.
During 2013, a key focus of our management team was to raise the awareness of our product portfolio in the U.S. and increase the amount of revenue we generated from the American market. These efforts have been well-timed as thousands of labs in the U.S. will need to utilize leading products to meet the burgeoning demand resulting from the passage of the Affordable Care Act. By partnering with Medline we position ourselves for even greater growth in 2014 and beyond while at the same time reducing our operating costs," commented Michaela Ott, co-president of MEDITE Group.
"We decided to partner with Medline after a comprehensive review of our competitive position in the U.S. and Canadian markets," added Ott. "We chose Medline because of its strategic focus on the $700 million histology market represented by an aggressive expansion into the segment beginning this year. This market is growing greater than 10 percent annually, so Medline recognized the dynamic growth opportunities and is devoting a significant amount of effort to building a leading histology system and consumables resource to hospitals and other healthcare providers. Medline elected to partner with us because of the breadth and quality of our product portfolio and our combined ability to provide cost effective solutions to the healthcare customer."
You call Updated on 25 June 2014 four months old? No wonder you lost your ass on this stock.
Biospectrum Asia article
It states that:
The product is likely to be submitted for regulatory approval in the US, Russia, Commonwealth of Independent states and other parts of the world in the near future. Cardium's contract manufacturing partner SAFC based in Carlsbad, California is expected to start commercial manufacture of Generx soon.
http://www.biospectrumasia.com/biospectrum/news/216642/us-bio-2014-a-gene-therapy-treat-heart-disease-promise
What ever happened to the Markman hearing that was set for last June 27th 2013?
Markman Hearing Date Set in Worlds Inc. vs. Activision Blizzard, Inc., Blizzard Entertainment, Inc. and Activision Publishing, Inc. Patent Infringement Lawsuit — U.S. District Judge Denise J. Casper has established a schedule for upcoming hearings and other case deadlines in Worlds Inc. (OTCBB: WDDD) vs. Activision Blizzard, Inc., Blizzard Entertainment, Inc. and Activision Publishing, Inc. (Activision Blizzard, Inc. et al) in Civil Action No, 1:12-CV-10576(DJC), a patent infringement lawsuit filed by Worlds Inc. on March 30, 2012 in the United States District Court for the District of Massachusetts. The patent claim construction hearing, also called a Markman hearing, is set for June 27, 2013, at which time the judge will be asked to issue rulings regarding the language and interpretation of the Worlds patents at issue in the case. Markman hearings are considered a critical event in a patent lawsuit. The Markman ruling will define the property rights for the technologies that Worlds has invented and has the right to exclusively practice. The court's Markman hearing decisions will drive and inform many aspects of the litigation.
And how MUCH was that offer? You should know that if you know one was made.
U dummber than a box of rocks
Go right ahead! Knock yourself out. I'm sure they'll laugh at u so hard they fall out of their chair!!!!!!!
Go right ahead! Knock yourself out. I'm sure they'll laugh at u so hard they fall out of their chair!!!!!!!
It won't be called CytoCore for much longer. They want to get rid of the nasty stigma that goes with that name and the past management. It's a shame that the crook and thief McCollough is even still part of this company.
It's obvious you are lacking in the knowledge of stock investing. They have 1.9 billion shares outstanding which to you means not much but to any investor who knows how a stock price goes up or down it means a lot and 1.9 billion shares is an outrageously HIGH amount of shares for a little bitty penny stock. The price WILL never move up or down especially with the small amount of trading volume this is getting.
Now if you had institutional investors come in and buy in 100,000 blocks it might move but....institutional investors won't buy stocks under $5.00 a share or some will limit it to $4.00
Also to get on the NASDAQ or AMEX you have to have a share price of $3.00 for 30 days straight I believe to list on there.
Soooooooooooooooooooo that is where the reverse split comes in. But they still have to get the share price up to around .10 cents a share then to do a 1 for 40 or 1 for 50. Or if they might do a 1 for 30 to get it to $3.00
And yes as i told you before the CEO told me they would do it when the time was right.
"Finally if you look at stocks such as BBW they do $390,000,000 annually with a share value of $14ps. There is only one conclusion here despite the BBW is a retailer and not in the IP sector."
BBW has only 16M shares outstanding and only 8.4M in the float so I don't see any correlation between the two.
By a buyout you mean Activision buying them out?
It's a NEW company now so that has NO bearing any longer. They have to and will do a reverse split. They have 1.9 billion shares outstanding. This stock will never move with that many shares. Their CEO stated to me that they will do one when the time is right.
How long does it take to litigate a patent infringement case?
Most cases either (1) settle within a year, or (2) settle/reach a final judgment within 2 years.
http://yazamip.com/node/100
This litigation is going on 2 years and 4 months. Worlds Filed in March 2012
They've got 1.9B (that is BILLION) shares outstanding. They'll be doing at least a 1 for 50 reverse split. That is if they can get the stock to .05-.10 cents. Maybe a 1 for 40
Dropped $1.20 on only 1200 shares is not a good sign. What I don't understand is why they would have done the reverse split without substanial news to put out. This thing will continue to drop unitl they put out great news. Will be back down under a $1.00 soon
The problem with the market now days is way too much day trading, swing trading, computer speed trading etc., not many buy and hold people left. It's hard for a small stock to grow when 75% of the investors are trading their stock instead of holding it.